Hui Jin Shin

Dr. Hui Jin Shin

Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA
orcid
Research fellow in neurogenetics, with clinical background i...

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
CBCarmen Barba
Carmen Barba
IBIngmar Blumcke
Ingmar Blumcke
MWMelodie R. Winawer
Melodie R. Winawer
THTill Hartlieb
Till Hartlieb
HKHoon-Chul Kang
Hoon-Chul Kang
OGon behalf of the SLC35A2 Study Group
on behalf of the SLC35A2 Study Group
Background and Objectives The SLC35A2 gene, located at chromosome Xp11.23, encodes for a uridine diphosphate–galactose transporter. We describe clinical, genetic, neuroimaging, EEG, and histopathologic findings and assess possible predictors of postoperative seizure and cognitive outcome in 47 patients with refractory epilepsy and brain somatic SLC35A2 gene variants. Methods This is a retrospective multicenter study where we performed a descriptive analysis and classical hypothesis testing. We included the variables of interest significantly associated with the outcomes in the generalized linear models. Results Two main phenotypes were associated with brain somatic SLC35A2 variants: (1) early epileptic encephalopathy (EE, 39 patients) with epileptic spasms as the predominant seizure type and moderate to severe intellectual disability and (2) drug-resistant focal epilepsy (DR-FE, 8 patients) associated with normal/borderline cognitive function and specific neuropsychological deficits. Brain MRI was abnormal in all patients with EE and in 50% of those with DR-FE. Histopathology review identified mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy in 44/47 patients and was inconclusive in 3. The 47 patients harbored 42 distinct mosaic SLC35A2 variants, including 14 (33.3%) missense, 13 (30.9%) frameshift, 10 (23.8%) nonsense, 4 (9.5%) in‐frame deletions/duplications, and 1 (2.4%) splicing variant. Variant allele frequencies (VAFs) ranged from 1.4% to 52.6% (mean VAF: 17.3 ± 13.5). At last follow-up (35.5 ± 21.5 months), 30 patients (63.8%) were in Engel Class I, of which 26 (55.3%) were in Class IA. Cognitive performances remained unchanged in most patients after surgery. Regression analyses showed that the probability of achieving both Engel Class IA and Class I outcomes, adjusted by age at seizure onset, was lower when the duration of epilepsy increased and higher when postoperative EEG was normal or improved. Lower brain VAF was associated with improved postoperative cognitive outcome in the analysis of associations, but this finding was not confirmed in regression analyses. Discussion Brain somatic SLC35A2 gene variants are associated with 2 main clinical phenotypes, EE and DR-FE, and a histopathologic diagnosis of MOGHE. Additional studies will be needed to delineate any possible correlation between specific genetic variants, mutational load in the epileptogenic tissue, and surgical outcomes.


1 January 2024 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
Hui Jin ShinHui Jin Shin
Hui Jin Shin
AKAra Ko
Ara Ko
SKSe Hee Kim
Se Hee Kim
JLJoon Soo Lee
Joon Soo Lee
HKHoon-Chul Kang
Hoon-Chul Kang
Shin HJ, et al. J Clin Neurol. 2024 May;20:e42. https://doi.org/10.3988/jcn.2023.0435

28 November 2022 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
Hui Jin ShinHui Jin Shin
Hui Jin Shin
JNJi-Hoon Na
Ji-Hoon Na
HLHyunjoo Lee
Hyunjoo Lee
YLYoung-Mock Lee
Young-Mock Lee

27 January 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
Hui Jin ShinHui Jin Shin
Hui Jin Shin
SRSeonae Ryu
Seonae Ryu
NLNaRae Lee
NaRae Lee
ELEunjoo Lee
Eunjoo Lee
AKAra Ko
Ara Ko
SKSe Hee Kim
Se Hee Kim
Objective: To assess the anti-seizure efficacy and safety of a C10-enriched medium-chain triglyceride (MCT) ketogenic diet (KD) compared with the classic KD in pediatric patients with refractory epilepsy.Methods: This 16-week, open-label, randomized, controlled, crossover pilot study was conducted at Severance Children’s Hospital, Seoul, South Korea, between August 2022 and September 2023. Fifteen pediatric patients with refractory epilepsy were enrolled and received classic KD and C10-enriched KD for 8 weeks each. The study compared seizure reduction rate, tolerability, and safety of the two diets.Results: Fifteen patients were enrolled. Patients were divided into 2 groups depending on the type of KD initiated. Ten patients completed the trial. Initial treatment with the C10-enriched KD resulted in seizure reduction in all five patients, with two becoming seizure-free. Initial treatment with classic KD was effective in two out of five patients. Upon crossover, those initially on C10-enriched KD maintained their seizure reduction, while patients initially on the classic KD showed additional seizure reduction when switched to C10-enriched KD. Adverse effects included transient hypoglycemia, metabolic acidosis, hypercalciuria, and gastrointestinal symptoms, all of which were manageable.Discussion: The C10-enriched KD demonstrated comparable efficacy and tolerability to the classic KD, offering a promising option for patients with refractory epilepsy who do not respond adequately to the classic KD alone. This study, the first to directly compare a C10-enriched KD with a classic KD, highlights the potential synergistic effects of decanoic acid.

1 January 2023 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
Hui Jin ShinHui Jin Shin
Hui Jin Shin
Ji-Hoon NaJi-Hoon Na
Ji-Hoon Na
HLHyunJoo Lee
HyunJoo Lee
YLYoung-Mock Lee
Young-Mock Lee
Shin HJ, et al. Yonsei Med J. 2023 Dec;64(12):705-711. https://doi.org/10.3349/ymj.2023.0080